New phase 1 entrants include Claudin18.2-targeting ADCs from Astra and Bolt.
ApexOnco Front Page
Recent articles
Three off-the-shelf mRNA therapies join intismeran autogene.
The honeymoon is over for Claudin18.2, as Elevation drops EO-3021.
While Sutro shows why it’s shelved luvelta-T.
YL217 will enter phase 1 before Sotio's similarly acting rival, licensed from Biocytogen.
The company buys Belgium’s EsoBiotec for $425m.
The acquisition of Araris follows a 2023 discovery collaboration.
At long last luvelta-T is shelved, and Sutro seeks a new focus.
